Status:
COMPLETED
Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's
Lead Sponsor:
GlaxoSmithKline
Conditions:
Parkinson's Disease
Parkinson Disease
Eligibility:
All Genders
30-70 years
Phase:
PHASE3
Brief Summary
This study evaluates how effective a new formulation of a marketed drug is in increasing the time to onset of dyskinesia (abnormal twisting, writhing movements) in patients with Parkinson's Disease wh...
Eligibility Criteria
Inclusion
- Must be on 600mg or less of levodopa therapy for two years or less.
- Must be on a stable dose of levodopa therapy for at least 4 weeks prior to screening.
Exclusion
- Current or past history of Dyskinesia.
- State of dementia or have a MMSE score \< 26 at screening.
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2006
Estimated Enrollment :
209 Patients enrolled
Trial Details
Trial ID
NCT00363727
Start Date
December 1 2003
End Date
January 1 2006
Last Update
January 18 2017
Active Locations (69)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Anniston, Alabama, United States, 36207
2
GSK Investigational Site
Birmingham, Alabama, United States, 35216
3
GSK Investigational Site
Birmingham, Alabama, United States, 35294
4
GSK Investigational Site
Phoenix, Arizona, United States, 85006